Medical Data Vision Co., Ltd.

3902.T
Health Information Services
2026/04/02 Updated
Market Cap: $401.4M (¥63.7B)
Stock Price: $10.60 (¥1,683)
Exchange Rate: 1 USD = ¥158.73

Notice Concerning the Issuance of Class A Preferred Shares by Third-Party Allotment and the Reduction of Capital Stock and Capital Surplus

On May 11, 2026, Medical Data Vision Co., Ltd. will issue 1 Class A preferred share by third-party allotment to Nippon Life Insurance Company at 17,249,077,446 yen, and simultaneously reduce capital stock and capital surplus to secure funds for share buyback.

Importance:
Page Updated: March 24, 2026
IR Disclosure Date: March 24, 2026

Key Figures

  • Number of Class A preferred shares issued: 1 share
  • Payment amount: 17,249,077,446 yen
  • Capital stock reduction amount: 8,624,538,723 yen

AI要約

Overview of Capital Policy

Medical Data Vision Co., Ltd. has resolved, as of May 11, 2026, to issue 1 Class A preferred share to Nippon Life Insurance Company by third-party allotment at 17,249,077,446 yen. Concurrently, the company will reduce capital stock and capital surplus by 8,624,538,723 yen each and transfer the amounts to other capital surplus through capital reduction. This capital increase and reduction are scheduled to take place after a share consolidation on the same day. The allottee aims to make the company a wholly owned subsidiary, securing funds and distributable amounts for share buyback. The Class A preferred shares carry no voting rights, so there will be no dilution of ordinary shares' voting rights.

Shareholder Composition and Future Outlook

Following this third-party allotment, Nippon Life Insurance Company will hold 100% of the Class A preferred shares, while ordinary shares will be held 55.56% by Nippon Life Insurance Company and 44.44% by SBI Holdings. Due to the share consolidation, other shareholders will hold fractional shares, effectively leaving only the allottee and SBI Holdings as shareholders. This capital increase and reduction are not expected to impact business performance, and the use of funds is deemed reasonable. The allottee’s payment funds have been confirmed to be covered by own capital.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.